78 Participants Needed

Azenosertib + Carboplatin + Pembrolizumab for Breast Cancer

FL
Overseen ByFilipa Lynce, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I need to stop my current medications to join the trial?

The trial requires that you stop any prior cytotoxic chemotherapy and biologic therapy at least 14 days before starting the study treatment. Additionally, you must not take any medications that are strong or moderate inhibitors or inducers of certain liver enzymes (CYP3A4/CYP3A5) and P-gp inhibitors, and these should be stopped before the trial as specified. Please consult with the trial team for specific guidance on your current medications.

What data supports the effectiveness of the drug combination Azenosertib, Carboplatin, and Pembrolizumab for breast cancer?

Research shows that combining pembrolizumab with carboplatin has been effective in treating certain types of breast cancer and lung cancer, improving survival rates and response to treatment. This suggests that the combination could potentially be beneficial for breast cancer as well.12345

Is the combination of Azenosertib, Carboplatin, and Pembrolizumab safe for humans?

Pembrolizumab, one of the drugs in the combination, has been used in various cancer treatments and is generally considered safe, but it can cause side effects like pneumonitis (lung inflammation) in 1%-5% of patients. Safety data for the specific combination with Azenosertib and Carboplatin is not available, but pembrolizumab has been studied extensively in combination with other drugs.678910

What makes the drug combination of Azenosertib, Carboplatin, and Pembrolizumab unique for breast cancer treatment?

This drug combination is unique because it combines Azenosertib, a novel agent, with Carboplatin, a chemotherapy drug, and Pembrolizumab, an immunotherapy, to target breast cancer in multiple ways, potentially enhancing effectiveness, especially in BRCA-related cases that are sensitive to DNA-damage agents.1271112

What is the purpose of this trial?

This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer.The names of the study drugs involved in this study are:* Azenosertib (a type of WEE1 inhibitor)* Carboplatin (a type of platinum compound)* Pembrolizumab (a type of monoclonal antibody)

Research Team

Filipa Lynce, MD - Dana-Farber Cancer ...

Filipa Lynce, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

This trial is for patients with metastatic triple-negative breast cancer. Participants should meet specific health criteria not detailed here.

Inclusion Criteria

Ability to understand and the willingness to sign a written informed consent document.
I can take care of myself but might not be able to do heavy physical work.
I can swallow pills.
See 15 more

Exclusion Criteria

My cancer has worsened despite having platinum-based chemotherapy.
Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
I do not have any uncontrolled illnesses.
See 24 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Phase 1: Dose Escalation

Participants are enrolled in a 3+3 dose-escalation scheme to establish the Maximum Tolerated Dose (MTD) of Azenosertib

Up to 27 weeks
CT or MRI scan every 9 weeks until 27 weeks

Phase 2: Treatment

Participants receive Azenosertib, Carboplatin, and Pembrolizumab with regular CT or MRI scans and tumor biopsies

Up to 48 months
CT or MRI scan every 9 weeks until 27 weeks, then every 12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Every 6 months
Follow-up visits every 6 months

Treatment Details

Interventions

  • Azenosertib
  • Carboplatin
  • Pembrolizumab
Trial Overview The study tests the safety and effectiveness of Azenosertib combined with Carboplatin and Pembrolizumab in treating metastatic triple-negative breast cancer.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Phase 2: AZENOSERTIB + PEMBROLIZUMAB + CARBOPLATINExperimental Treatment3 Interventions
Participants will complete: * Baseline visit with CT or MRI scan and tumor biopsy. * CT or MRI scan every 9 weeks until 27 weeks then every 12 weeks. * Cycle 1 through End of Treatment: * Days 1 through 5, 8 through 12, and 15 through 19 of 21 Day Cycle: Predetermined dose of Azenosertib 1x daily. * Day 1 of 21 Day Cycle: Predetermined dose of Pembrolizumab 1x daily. * Days 1 and 8 of 21 Day Cycle: Predetermined dose of Carboplatin 1x daily. * Tumor biopsy during Cycle 2. * End of Treatment visit * Follow up: every 6 months
Group II: Phase 1: Dose Escalation ArmExperimental Treatment3 Interventions
Participants will be enrolled in a standard 3+3 dose-escalation scheme to establish a Maximum Tolerated dose (MTD) of Azenosertib, starting at Dose Level 0, de-escalating to Dose Level -1, and escalating to Dose Levels 1 and 2. * Baseline visit with CT or MRI scan. * CT or MRI scan every 9 weeks until 27 weeks then every 12 weeks. * Cycle 1 through End of Treatment: * Days 1 through 5, 8 through 12, and 15 through 19 of 21 Day Cycle: Predetermined dose of Azenosertib 1 x daily. * Day 1 of 21 Day Cycle: Predetermined dose of Pembrolizumab 1x daily. * Days 1 and 8 of 21 Day Cycle: Predetermined dose of Carboplatin 1x daily. * End of Treatment visit * Follow up: every 6 months * Dose de-escalation and escalation will follow dose-limiting toxicities specifications (DLTs) per the protocol. The MTD is the highest dose level with ≤1 DLT in a cohort of 6 participants and the study will proceed to Phase 2.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Filipa Lynce, MD

Lead Sponsor

Trials
2
Recruited
140+

Zentalis Pharmaceuticals

Collaborator

Trials
2
Recruited
80+

Merck Sharp & Dohme LLC

Industry Sponsor

Trials
4,096
Recruited
5,232,000+
Chirfi Guindo profile image

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis profile image

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

Findings from Research

In a phase II study involving 22 patients with BRCA1/2-related metastatic breast cancer, the combination of pembrolizumab and carboplatin showed an overall response rate (ORR) of 43% and a disease control rate (DCR) of 76%, indicating some level of efficacy, particularly in luminal tumors.
Despite the promising results, the study did not meet its primary aim of achieving an ORR of 70%, leading to its termination; however, the safety profile was acceptable with only 22.7% of patients experiencing grade ≥3 adverse events.
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA).Cortesi, L., Venturelli, M., Cortesi, G., et al.[2023]
In a real-life study of 121 patients with advanced non-squamous non-small cell lung cancer, the combination of pembrolizumab and chemotherapy resulted in a median progression-free survival of 9 months and overall survival of 20.6 months, demonstrating its efficacy as a first-line treatment.
The treatment was generally well-tolerated, with manageable side effects; however, 17.5% of patients experienced grade 3-4 adverse events, and there were two treatment-related deaths, indicating the need for careful monitoring during therapy.
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29).Renaud, E., Ricordel, C., Corre, R., et al.[2023]
In a long-term study of 123 patients with advanced nonsquamous NSCLC, the combination of pembrolizumab with pemetrexed-carboplatin significantly improved the objective response rate (58% vs. 33%) and progression-free survival (24.5 months vs. 9.9 months) compared to chemotherapy alone.
Patients who completed 2 years of pembrolizumab treatment had a remarkable 92% survival rate at the data cutoff, indicating a durable clinical benefit, while the safety profile remained manageable with no new safety concerns identified.
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.Awad, MM., Gadgeel, SM., Borghaei, H., et al.[2021]

References

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA). [2023]
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). [2023]
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. [2021]
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). [2022]
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. [2020]
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. [2023]
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. [2022]
Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis. [2023]
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. [2022]
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
New Approved Use for Keytruda. [2022]
A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. [2015]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security